Exercise intervention for the management of chemotherapy-induced peripheral neuropathy: A systematic review and network meta-analysis

Natsuki Nakagawa[*,1], Sena Yamamoto[*,2], Akiko Hanai[3], Ayano Oiwa[4], Harue Arao[5]

[*]These two authors contributed equally to this work.

[1]Department of Respiratory Medicine, The University of Tokyo Hospital, Department of Respiratory Medicine, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-8655, Japan; nnakagawa-tky@umin.ac.jp

[2]Division of Health Sciences, Osaka University Graduate School of Medicine, 1-7 Yamadaoka, Suita, Osaka 565-0871, Japan; s-yamamoto@sahs.med.osaka-u.ac.jp

[3]Advanced Data Science Project, RIKEN, Yokohama

[4]Department of Anesthesiology, Division of Pain Clinic, The Jikei University School of Medicine, Tokyo, Japan

[5]Division of Health Sciences, Osaka University Graduate School of Medicine, 1-7 Yamadaoka, Suita, Osaka 565-0871, Japan; h-arao@sahs.med.osaka-u.ac.jp

CORRESPONDING AUTHOR

Akiko Hanai

Medical Data Mathematical Reasoning Team, Advanced Data Science Project, RIKEN

Information R&D and Strategy Headquarters, RIKEN

W507/509, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama City, Kanagawa 230-0045, Japan

(akiko.hanai@riken.jp)

ABSTRACT

Purpose: Although exercise is recommended for cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN), the effective types of exercise for preventing and treating CIPN remain unclear. This systematic review and network meta-analysis (NMA) aimed to evaluate the comparative effects of exercise on CIPN.

Methods: We included relevant randomized controlled trials (RCTs) identified in a 2019 systematic review that evaluated the effects of exercise on CIPN and conducted an additional search for RCTs published until 2023. We evaluated the risk of bias for each RCT; the comparative effectiveness of exercise on patient-reported quality of life (QOL) through an NMA; and the effectiveness of exercise on QOL scores, patient-reported CIPN symptoms, and pain through additional meta-analyses.

Results: Twelve studies (exercise, n=540; control, n=527) comparing 8 exercise interventions were included in the analysis. All studies were determined to have a high risk of bias. The meta-analyses showed significantly improved QOL (standard mean differences [SMD] 0.45; 95% confidence interval [CI] = 0.12 to 0.78) and CIPN symptoms (SMD 0.46; 95% CI = 0.11 to 0.82). No severe adverse events were reported. Pain tended to improve with exercise (SMD 0.84; 95% CI = -0.11 to 1.80). An NMA suggested that the interventions of combination of balance and strength training showed the significant improvement in QOL scores compared to the control.

Conclusion: Exercise interventions are safe and effective in improving QOL. For exercise categories, the combination of balance and strength training would be the promising program. Patients with CIPN will benefit from frequent exercise focusing on the declined symptoms.

KEYWORDS: Cancer, Chemotherapy, Neurotoxicity, Physical Activity, Quality of Life,

Strengths and Limitations of This Study

- It organized the details of exercise regimens used in clinical trials and their adherence. It considered the diversity of exercise frequencies and types to ensure adequate and comprehensive analysis of exercise interventions in the management of CIPN.
- We included the exercise clinical trials for cancer patients who underwent chemotherapy. However, the timing of exercise interventions (prevention or intervention), type of cancer, and chemotherapy regimen used were not stratified.
- Network meta-analysis methods were used to analyze differences in intervention effects by type of exercise. However, the robustness of the inclusion and exclusion of studies is a limitation that prevents us from drawing clear conclusions. The generalizability of the findings is because of the reliance on the small sample size and exploratory nature of the exercise clinical trials, and there remained a risk that the bias may influence the results.

INTRODUCTION

Approximately half of adult cancer patients receiving neurotoxic chemotherapy experience chemotherapy-induced peripheral neuropathy (CIPN) [1], which frequently continues after chemotherapy cessation, sometimes for years [1-3]. CIPN can result in dose reduction or discontinuation of cancer chemotherapy [4, 5]. The rebellious and chronic nature of CIPN can lead to functional and psychiatric impairment, including slower gait and a higher risk of falls compared to cancer patients without CIPN [6-8]. Therefore, CIPN can seriously adversely affect quality of life (QOL) [2]. It also causes an economic burden due to the long-term prescription of ineffective analgesics for chronic CIPN [9]. However, recent clinical guidelines for CIPN indicate that it is difficult to establish effective management of CIPN, except that some patients may benefit from duloxetine as only a partial symptomatic treatment [10, 11].

Previous studies have reported that physical activity and exercise improve cardiovascular fitness, muscle strength, health-related QOL, depression, cachexia, and cancer-related fatigue [12-15]. Indeed, the guidelines of the American Society of Clinical Oncology (ASCO) for patients receiving active cancer treatment recommend regular exercise as supportive or palliative care [16].

Although exercise therapy for CIPN mitigation has not been established as part of any established guideline, several systematic reviews imply the potential efficacy of exercise for the prevention and treatment of symptoms related to CIPN [10, 11, 13, 17-19]. In these studies, the dose, frequency, intensity, and duration of exercise programs varied (i.e., ranging from inactivity avoidance instructions to resistance training), and the outcome (e.g., specific sensorimotor functions, activities of daily living, QOL) also varied across the studies. According to the ASCO CIPN guidelines, exercise therapy is not currently recommended as a preventative or treatment

approach for CIPN because of the low quality of the available evidence based on a systematic review of the literature published between January 2013 and August 2019 [10]. The guidelines state that further robust research is necessary to determine the efficacy and potential risks of exercise therapy [10]. In a systematic review conducted by Lin et al. [17], the overall mean effect size was estimated using standardized mean differences and a fixed-effect model, and significant improvement in the exercise cohort compared to the control group was reported (mean difference: 0.5319; 95% confidence interval: 0.2295 to 0.8344; Z = 3.45) . However, the study suggested the need for further investigation of different exercise protocols and intervention intensities with larger sample sizes and more specific outcome measures [17]. Since the publication of these systematic reviews, additional clinical trials of exercise on CIPN have been published.

Therefore, we aimed to update the systematic reviews of randomized controlled trials (RCTs) included in the ASCO clinical guidelines by incorporating additional recently published studies evaluating the effect of exercise on the mitigation of CIPN symptoms with an additional focus on the type of exercise program. Since CIPN symptoms and their incidence rate vary by assessment measurements [20], a consensus has been reached that clinical trials investigating CIPN should include an assessment of QOL as an indicator that best reflects the patient's life state considering various complex symptoms [21]. We conducted a meta-analysis with QOL as a primary outcome, and specific outcomes of CIPN symptoms were also analyzed to capture changes in CIPN symptoms associated with exercise interventions. To focus on the details and diversity of exercise intervention programs, we conducted a network meta-analysis (NMA) to determine which exercise interventions were most effective in improving QOL.

METHODS

This systematic review and meta-analysis followed the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [22]. The review protocol was prospectively registered with the University Hospital Medical Information Network Clinical Trials Registry (UMIN000045558). Ethical approval and informed consent were waived considering the nature of the study. This study was conducted as a part of the Japanese clinical practice guidelines on CIPN and was based on a clinical guideline previously published by ASCO [10]. Therefore, in the scope of guideline development, the choice was made to include all randomized controlled trials comprising the ASCO systematic review as part of the current analysis [23, 24].

Literature search

In accordance with the guideline committee policy, a systematic literature search targeted studies published after September 2019 because a previous systematic literature search had been conducted in earlier clinical guidelines published by ASCO [10]. A systematic literature search was performed in PubMed on April 20, 2023, to identify RCTs published between September 1, 2019, and April 20, 2023, that evaluated the effects of exercise on CIPN and included more than 5 patients in the exercise group. Interventions specialized only for the upper or lower extremities were excluded. Table S1 presents the search terms used in the publication search strategy. The literature search in PubMed was restricted to articles published in peer-reviewed journals and written in English. In addition to the systematic literature search, we evaluated studies manually obtained primarily by reviewing previously reported clinical guidelines and systematic reviews [10, 11, 13, 17, 25]. Two authors independently screened each study for eligibility, and

disagreements among reviewers were resolved through discussion.

Data extraction

Two reviewers (SY and NN) independently collected the following information from each included study using a predefined data extraction form: (1) general information about the study (author, year of publication, country, and study design); (2) sample size; (3) patient characteristics (age, sex, cancer type, anticancer drugs that could induce peripheral neuropathy, and the presence of baseline CIPN); (4) exercise type, intensity, duration and frequency; (5) examined outcomes, including CIPN; (6) timing of assessment of outcomes; (7) adverse effects related to the intervention; and (8) enrollment rate, completion rate of the study, and adherence to the intervention. The outcome measures were grouped into six categories referring to a MASCC book [25] as follows: (1) QOL (primary outcome); (2) patient-reported CIPN; (3) pain; (4) clinical assessments of CIPN signs; (5) balance measures; and (6) physical functional assessments. The enrollment rate was defined as the proportion of screened persons who were randomly assigned. The completion rate was defined as the proportion of randomly assigned persons for whom a final analysis was performed. The definition of adherence to exercise intervention followed the individual studies. Discrepancies between the reviewers were resolved through discussion or by a third reviewer (HA).

Quality assessment

Two reviewers (SY and NN) independently assessed the risk-of-bias using version 2 of the Cochrane risk-of-bias tool for randomized trials (RoB 2) [26]. All disagreements among reviewers were resolved through discussion. Risk-of-bias assessments were summarized in a

traffic-light plot using Risk-of-bias VISualization (robvis) [27]. We could not assess the risk of bias, such as heterogeneity among the studies or publication bias, across the studies because many studies included outcomes of different types of measurements and did not specify a primary outcome variable. A funnel plot was used to check for the presence of publication bias.

Data synthesis and meta-analyses

We conducted a meta-analysis on outcome data regarding QOL (primary outcome), patient-reported CIPN symptoms, pain, and collected postintervention or a time point similar to postintervention. We included the studies that reported the data able to calculate the mean and standard deviation at each point. The standardized mean difference (SMD) was calculated due to different scales used across the study outcome measures. Confidence intervals were calculated as a measure of precision for the SMD estimates. If data were unavailable, we contacted the authors and used all data provided by the authors after contact. If a trial was conducted with multiple parallel arms including different types of exercise, we compared the outcomes by combining the arms against a control. The overall mean effect sizes were estimated using random-effects models. Heterogeneity was evaluated with chi-squared tests and *I*-square tests. We used Review Manager (RevMan, Version 5.4., The Cochrane Collaboration, 2020) for the meta-analysis.

Network meta-analysis of exercise intervention effectiveness and QOL

A NMA was conducted to assess the comparative effectiveness of the different exercise interventions in each trial, and the results represent estimates of the relative effects between any given intervention pair in the NMA of QOL. The NMA was conducted using the "BUGSnet" package in R and was based on Bayesian methods [28]. We specified 100,000 iterations with

10,000 burn-ins and 10,000 adaptations based on random- and fixed-effects models and compared their accuracies; we employed the model with the lowest deviance information criterion (DIC) and used Bayesian Markov chain Monte Carlo modeling. The treatments were ranked according to cumulative rank curve under surface (SUCRA) probabilities.

RESULTS

Overview of the included literature

A total of 1640 studies that were identified for screening after applying the search terms described in Table S1 were screened, and 4 studies [24, 29-31] were included in the final analysis. In addition, the 2 studies [23, 32] included in the update to the ASCO guideline [10] and 6 additional studies [33-38] referred to in previous systematic reviews [11, 13, 17, 25] were included. In total, 12 randomized controlled trials were included in the qualitative synthesis (Figure 1).

Details on these studies, such as patient disease diagnosis, exercise intervention, and outcome measures, are provided in Table 1.Two-arm (exercise vs. control) study designs were used in 8 studies [23, 24, 31-36]; 3-arm designs were used in 2 studies [29, 30]; and 4-arm designs were used in 2 studies [37, 38]. The control conditions included usual care, education only, and different types of nonpharmacological interventions (Reiki, meditation, cold application). All the included studies aimed to assess the efficacy of exercise on CIPN. Intention-to-treat analysis was conducted in 5 studies [23, 24, 30, 31, 38], and per-protocol analysis was conducted in 2 studies [29, 33]. In the remaining 5 studies [32, 34-37], it was unclear which analysis was conducted or how missing data were treated.

Risk-of-bias assessment

The risk of bias was assessed by funnel plots (Figure S1), which were asymmetric and biased toward positive outcomes, and by the RoB 2 tool (Figure S2). For randomization, 5 studies [24, 30, 32, 35, 36] were identified as having a high risk or some concerns for risk-of-bias, as they did not report detailed information about randomization and/or concealment, and one study clearly described that randomization was not masked [37]. For deviation, all 12 studies were evaluated to have a high risk of bias. For missing outcome data, 11 studies were identified as high risk or with some concerns for risk-of-bias due to participants dropping out during the study [23, 24, 29-37]. For measurement of the outcomes, 10 out of 12 studies were evaluated to have a high risk-of-bias because outcome assessors were often involved in the studies and were aware of the intervention [23, 24, 29, 30, 32-34, 36-38]. Finally, for selection in the reported results, 3 studies were evaluated to have a high risk-of-bias because of discrepancies in the description between the methodology and reported results [24, 35, 38].

Study and patient characteristics

The sample sizes of the included studies ranged from 22 to 456 patients. In 6 studies [23, 24, 30, 34, 36, 37], the presence of CIPN before randomization was the eligibility criterion for the respective studies, while in 1 study [29], the absence of CIPN was the eligibility criterion. Patients with breast and gastrointestinal cancers formed the largest population. In all included studies, neurotoxic drugs were cytotoxic agents, and patients with CIPN caused by immune checkpoint inhibitors were excluded.

Intervention details

The types of exercise interventions consisted of balance training (9 studies) [23, 24, 29, 30, 33-36, 38], strength training (7 studies) [23, 24, 29, 30, 32, 33, 35], aerobic training (4 studies) [23, 31-33], and yoga [37]. Balance training interventions mainly consisted of standing balanced on an unstable platform under prescribed rules. Seven studies used a combination of different types of exercises [23, 24, 29, 30, 32, 33, 35]. In 4 studies [24, 30, 32, 36], the intervention was conducted at home, largely unsupervised, with participants self-reporting their adherence. In 5 other studies [23, 33, 34, 37, 38], the intervention was conducted in the clinic, hospital or sports center, mostly under basic supervision, with an objective assessment of adherence. In one study, participants could choose the place where they would exercise [29]. The length of the interventions ranged from 4 to 36 weeks in 11 studies [23, 24, 30-38]. In 1 study [29], the intervention continued during chemotherapy, and the intervention duration was not decided beforehand. As shown in Table 1, the frequency of exercise differed between the studies, ranging from 2 times a week to daily. Likewise, the length of time in which participants were engaged in exercise varied in each study. Most exercise interventions required less than an hour for each session. The intensity of aerobic exercise was adjusted based on the participants' heart rate in all 3 studies in which the intervention included aerobic exercise [23, 32, 33]. Moreover, the intensity was adjusted based on individual capacity [23, 29, 30, 32, 33, 35] in 6 of the 7 studies in which the intervention included strength training. For other types of intervention, the intensity was maintained at a fixed level.

Outcome measurement tools

The primary outcome measures of each study are described in Table 1. Patient-reported

CIPN was the most frequent outcome measured (9 studies) [23, 24, 29-32, 34, 37, 38], and QOL was assessed in 8 studies [23, 24, 29, 31, 33, 35, 37, 38]. Only one study evaluated the chemotherapy completion rate [29], but none of the studies assessed outcomes related to chemotherapy, including chemotherapy dose received or survival (Table 2).

Effectiveness of exercise on patient-reported outcomes of QOL

Two studies [24, 33] reported a significant intervention effect on QOL. Two studies assessed QOL using the European Organization for Research and Treatment of Cancer core quality of life questionnaire (EORTC-QLQ-C30) [39], and one study assessed QOL using FACT-Taxane [40]. The other studies [23, 29, 35, 37, 38] did not detect significant differences in QOL and were assessed with the EORTC-QLQ-C30 or the Functional Assessment of Cancer Therapy-General (FACT-G) questionnaire [41]. The synthesized data from 5 studies [23, 24, 29, 31, 37] revealed that exercise significantly improved QOL (SMD, 0.45; 95% CI = 0.12 to 0.78, P = 0.008, I^2 = 31%) (Figure 2A).

Effectiveness of exercise for patient-reported CIPN symptoms

Four studies [23, 24, 30, 32] reported significant intergroup differences in patient-reported symptoms related to CIPN, whereas four studies [29, 31, 34, 38] did not detect significant differences. One study compared pre- and postintervention data and reported that neuropathic symptoms significantly worsened only in the control group [37]. Although three studies [23, 37, 38] assessed patient-reported CIPN symptoms using the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group Neurotoxicity (FACT-GOG-NTX) questionnaire [42], the results were inconsistent. The six studies [23, 24, 29, 31, 32, 37] included in the meta-analysis showed a significant intervention effect on patient-reported CIPN symptoms

(SMD, 0.46; 95% CI = 0.11 to 0.82, P = 0.01, I^2 = 66%) (Figure 2B). Fear of falling was not included as a patient-reported CIPN symptom in the meta-analysis because of high heterogeneity [29, 34].

Adverse events related to exercise

Nine studies [23, 24, 29, 32-36, 38] reported adverse events; however, of these, only Müller et al. [29] reported adverse events related to the exercise programs, in which pain, fatigue and dizziness occurred in 21-25% of patients in the exercise group [29].

Both studies where pain was measured using pain scales [24, 38] reported a significant reduction in pain in the exercise group compared to the control group. There were no significant differences in pain scores on the Chemotherapy-Induced Peripheral Neuropathy Assessment Tool (CIPNAT) [30] or the EORTC-QLQ-C30 [29, 33, 38]. A forest plot showed no significant difference between the exercise groups and control groups, but a trend towards a favorable effect of exercise was observed (SMD, 0.84; 95% CI = -0.11 to 1.80, P = 0.08, I^2 = 91%) (Figure 2C).

Clinical assessments of CIPN post-exercise intervention

Clinical assessments of CIPN symptoms were significantly improved by exercise in 2 out of 3 studies [31, 33, 38]. The beneficial effects of the intervention included improvements in peripheral deep sensitivity [33, 38] and Achilles tendon and patellar tendon reflexes [38]. Significant intervention effects on balance ability were observed in all relevant studies [23, 29, 33-36]. However, outcomes related to balance involved multiple measures and a wide range of signs. Mixed results were observed for physical function. Four studies reported benefits to muscle strength [23, 29, 35] and SPPB [31], while three studies did not show beneficial effects

[33, 34, 36].

Enrollment, completion rate and adherence

Patient enrollment rates were described in 7 studies [24, 29-31, 34, 35, 37] and ranged from 25 to 100% (Table S2). Two studies [24, 35] described the reasons for the decrease in the enrollment rate, including lack of interest, personal reasons, and unfulfilled eligibility criteria. Completion rates were described in all studies and ranged from 64 to 100%. Six studies [23, 32, 34, 36-38] described the reasons for the decrease in the completion rate, including death, disease progression, and physical, psychological, and personal reasons. Adherence to the interventions was described in 8 studies [23, 24, 29, 31-33, 36, 38] and ranged from 49 to 98%. Two studies [29, 36] described the details of the reasons for the decrease in adherence, including side effects of anticancer treatment, time constraints and motivation.

Network meta-analysis of exercise interventions on QOL

A NMA was conducted to compare the effectiveness of each exercise intervention on QOL and included each trial arm for which a QOL index was available [23, 24, 29, 37] (Figure 3A. network graph). The fixed-effects model was selected for this data set.

In the SUCRA plot (Figure 3B), the curve associated with the combination treatment balance and strength training had the highest probability of being ranked first among treatments, suggesting that it is most likely to result in improved QOL scores. The model also generates effect estimates. The difference between balance and strength training and the other treatments was larger than that of the control and balance training (Figure 3C).

DISCUSSION

The meta-analyses indicated that exercise was effective in improving QOL scores and patient reported CIPN symptoms. The results of the NMA on specific exercise interventions showed that the combination of balance and strength training provided the greatest benefit to QOL over the control. Severe adverse events regarding exercise were reported to be rare, and the meta-analysis showed that pain status after the exercise intervention tended to be positive in the intervention group. Considering these findings, exercise interventions that include strength training confer the greatest benefit for CIPN.

Our analysis with updated trials indicated that exercise positively affected QOL, consistent with previous systematic reviews that showed that exercise resulted in an improvement in QOL scores (SMD: 14.62, 95% CI, 6.03-3.20) [19, 43]. The exercise interventions differed among the 12 studies included in this systematic review. Concerning intervention programs, a daily home-based program combining balance and strength training was suggested to have the greatest improvement in QOL compared with that of the control group, but the differences were not statistically significant in the NMA. While most of the other studies included in this analysis used an exercise frequency of 2-3 times per week, the trial that used the Strength + Balance exercise intervention had a daily home-based intervention, suggesting that a high frequency of specialized exercise was implemented. These results are similar to those of a clinical trial that compared different doses and modes of exercise for breast cancer patients who underwent chemotherapy and showed that compared with standard volumes, a higher volume of aerobic or combined exercise may better manage declines in physical functioning and worsening symptoms [44]. Although exercise relieves general chronic pain, it causes acute muscle pain [45]; however, the results of this study suggest that strength exercise does not cause pain in

patients with CIPN. In cancer patients, intrapersonal factors (functional status or pain, interest in exercise, and beliefs about the importance of exercise) are related to low physical activity [46]. However, it is recommended for general cancer survivors to avoid physical inactivity and perform at least 150-300 minutes of moderate-intensity exercise or 75 minutes of high-intensity exercise, or an equivalent combination, per week, with at least two days of resistance training (muscle strengthening exercise) [15, 47]. Implementing these common exercise recommendations for cancer survivors is expected to improve pain and remove the barriers to exercise. The results of this NMA suggest that a program that adds balance training to these exercise recommendations may help improve the QOL of CIPN patients.

There are two limitations of this research. First, the included studies are predominantly small exploratory studies with limited information, and it is difficult to exclude the possibility that study biases may have led to positive results. It is recommended that the effect-size metrics selected for the meta-analysis be comparable and reliable, but none of them are perfect in this report. The funnel plot results were asymmetric and biased towards positive outcomes, which indicates selection bias. There are several reasons why bias may have been observed, including protocol deviations due to individual differences in exercise performance, self-reported outcome measures, nonblinded interventions, and the possibility of survival bias among patients with high adherence to the described study protocols. In addition, CIPN symptoms are influenced by the type and schedule of chemotherapy, but no study has established or described those factors in detail. Therefore, differences in the target population may have influenced the results. The consideration of these sources of potential bias is important when interpreting the results of these exercise interventions. Furthermore, isolating an actual intervention effect from a placebo effect is difficult to achieve, as participation in a study itself may lead to improvements in motivation

and physical and mental function. Altogether, this highlights the clinical importance of conducting a meta-analysis and NMA to consider the totality of evidence that supports the claim for exercise in the management of CIPN.

Second, many trials did not specify whether the tested intervention was intended to prevent or treat CIPN. Since symptoms of CIPN can occur in either limb, interventions should ensure that assessments are made at the site of CIPN onset. However, it is difficult to predict the CIPN site and complete a functional assessment and intervention by the site in the research framework, especially in prevention research. For future research, it is important to design exercise interventions with multiple effects and evaluation methods, such as large-scale clinical trials with subgroup analysis, in advance.

Based on the results of this study, it is expected that not only would a reduction in CIPN symptoms improve QOL but also that an improvement in basic physical functions, such as underlying physical fitness, has a synergistic effect of enabling a more active lifestyle and improving QOL. The present NMA could not show the significant effects but suggested that a combination of balance and strength training, which require the supervision of exercise specialists and the creation of an appropriate environment. The implementation of active lifestyles is recommended [15], and they can be easily introduced into the daily lives of cancer patients. However, our NMA results suggest that high-frequency combined strength and balance exercise interventions are preferable for reducing CIPN, which requires more specialized guidance than general lifestyle physical activities.

CONCLUSION

Our results indicate that the exercise interventions implemented in the RCTs are effective

in improving QOL and CIPN symptoms. While increasing physical activity would enhance general QOL and aerobic exercise is observed to be an effective approach, the combination of balance and strength training provides the great benefits in CIPN patients. Our meta-analysis results strengthen the evidence that exercise benefits the QOL of CIPN patients. Furthermore, daily exercise with a combination of balance and strength training would promise for improving QOL.

Further research on how to implement a system incorporating more specialized and intense exercise in this patient population is needed to achieve exercise implementation based on an assessment of balancing ability and efficient strength training on a continuous basis.

ACKNOWLEDGEMENTS

We would like to thank the authors of the original papers who provided us with information for this study.

COMPETING INTERESTS

Financial interests: The authors declare they have no financial interests.

Non-financial interests: A.H. is the chair of the CIPN guideline committee of the Japanese Association of Supportive Care in Cancer (JASCC) and H.A. is a member of the CIPN guideline committee. All the authors are unpaid members of the systematic review team of the CIPN guideline committee of JASCC.

FUNDING

This work was supported by a JSPS Grant-in-Aid for Research Activity Start-up (19K21293) for A.H.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

AUTHOR CONTRIBUTIONS

All authors contributed to the idea for the article and the search strategy planning. NN, SY, AO and HA conducted screening of the articles. NN and SY performed data extraction and quality assessment. AO and HA contributed to review of the data. NN, SY, and AH drafted the manuscript. AO and HA critically revised the drafted manuscript. All authors have reviewed and approved the submitted version of the manuscript.

ETHICS APPROVAL

Not applicable.

INFORMED CONSENT

Not applicable.

Patient and Public Involvement

Not applicable for this research.

AUTHOR INFORMATION

Authors and Affiliations

Department of Respiratory Medicine, The University of Tokyo Hospital, Tokyo, Japan

Natsuki Nakagawa*(0000-0001-8832-0807)

Division of Health Sciences, Osaka University Graduate School of Medicine, Osaka, Japan

Sena Yamamoto*(0000-0002-7961-697X), Harue Arao (0000-0001-9747-9828)

Medical Data Mathematical Reasoning Team, Advanced Data Science Project, Information R&D and Strategy Headquarters, RIKEN, Kanagawa, Japan

Akiko Hanai (0000-0003-4468-1488)

Department of Anesthesiology, The Jikei University School of Medicine, Tokyo, Japan

Ayano Oiwa (0000-0003-0994-0050)

ETHICS DECLARATIONS

Consent for publication

Not applicable.

REFERENCES

1 Seretny M, Currie GL, Sena ES, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain 2014;155:2461–70. doi: 10.1016/j.pain.2014.09.020

2 Mols F, Beijers T, Vreugdenhil G, van de Poll-Franse L. Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review. Support Care Cancer 2014;22(8):2261-9. doi: 10.1007/s00520-014-2255-7

3 Kneis S, Wehrle A, Müller J, et al. It's never too late - balance and endurance training improves functional performance, quality of life, and alleviates neuropathic symptoms in cancer survivors suffering from chemotherapy-induced peripheral neuropathy: results of a randomized controlled trial. BMC Cancer 2019;19:414. doi: 10.1186/s12885-019-5522-7

4 DiBonaventura MD, Copher R, Basurto E, et al. Patient preferences and treatment adherence among women diagnosed with metastatic breast cancer. Am Health Drug Benefits 2014;7:386–96.

5 Lyman GH. Impact of chemotherapy dose intensity on cancer patient outcomes. J Natl Compr Canc Netw 2009;7:99–108. doi: 10.6004/jnccn.2009.0009

6 Winters-Stone KM, Horak F, Jacobs PG, et al. Falls, functioning, and disability among women with persistent symptoms of chemotherapy-induced peripheral neuropathy. J Clin Oncol 2017;35:2604–12. doi: 10.1200/jco.2016.71.3552

7 Shah A, Hoffman EM, Mauermann ML, et al. Incidence and disease burden of chemotherapy-induced peripheral neuropathy in a population-based cohort. J Neurol Neurosurg Psychiatry 2018;89:636–41. doi: 10.1136/jnnp-2017-317215

8 Kolb NA, Smith AG, Singleton JR, et al. The association of chemotherapy-induced peripheral neuropathy symptoms and the risk of falling. JAMA Neurol 2016;73:860–6. doi: 10.1001/jamaneurol.2016.0383

9 Bao T, Basal C, Seluzicki C, et al. Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk. Breast Cancer Res Treat 2016;159:327–33. doi: 10.1007/s10549-016-3939-0

10 Loprinzi CL, Lacchetti C, Bleeker J, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update. J Clin Oncol 2020;38:3325–48. doi: 10.1200/jco.20.01399

11 Jordan B, Margulies A, Cardoso F, et al. Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up. Ann Oncol 2020;31:1306–19. doi: 10.1016/j.annonc.2020.07.003

12 Hong Y, Wu C, Wu B. Effects of resistance exercise on symptoms, physical function, and quality of life in gastrointestinal cancer patients undergoing chemotherapy. Integr Cancer Ther 2020;19:1534735420954912. doi: 10.1177/1534735420954912

13 Duregon F, Vendramin B, Bullo V, et al. Effects of exercise on cancer patients suffering chemotherapy-induced peripheral neuropathy undergoing treatment: a systematic review. Crit Rev Oncol Hematol 2018;121:90–100. doi: 10.1016/j.critrevonc.2017.11.002

14 Fuller JT, Hartland MC, Maloney LT, et al. Therapeutic effects of aerobic and resistance exercises for cancer survivors: a systematic review of meta-analyses of clinical trials. Br J Sports Med 2018;52:1311. doi: 10.1136/bjsports-2017-098285

15 Campbell KL, Winters-Stone KM, Wiskemann J, et al. Exercise guidelines for cancer

survivors: consensus statement from international multidisciplinary roundtable. Med Sci Sports Exerc 2019;51:2375–90. doi: 10.1249/mss.0000000000002116

16 Ligibel JA, Bohlke K, May AM, et al. Exercise, diet, and weight management during cancer treatment: ASCO guideline. J Clin Oncol 2022;40:2491–507. doi: 10.1200/jco.22.00687

17 Lin WL, Wang RH, Chou FH, et al. The effects of exercise on chemotherapy-induced peripheral neuropathy symptoms in cancer patients: a systematic review and meta-analysis. Support Care Cancer 2021;29:5303–11. doi: 10.1007/s00520-021-06082-3

18 Kanzawa-Lee GA, Larson JL, Resnicow K, et al. Exercise effects on chemotherapy-induced peripheral neuropathy: a comprehensive integrative review. Cancer Nurs 2020;43:E172–85. doi: 10.1097/ncc.0000000000000801

19 Lopez-Garzon M, Cantarero-Villanueva I, Postigo-Martin P, et al. Can physical exercise prevent chemotherapy-induced peripheral neuropathy in patients with cancer? A systematic review and meta-analysis. Arch Phys Med Rehabil 2022;103:2197–208. doi: 10.1016/j.apmr.2022.02.008

20 Molassiotis A, Cheng HL, Lopez V, et al. Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy. BMC Cancer 2019;19:132. doi: 10.1186/s12885-019-5302-4

21 Dorsey SG, Kleckner IR, Barton D, et al. The national cancer institute clinical trials planning meeting for prevention and treatment of chemotherapy-induced peripheral neuropathy. J Natl Cancer Inst 2019;111:531–37. doi: 10.1093/jnci/djz011

22 Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated

guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71

23 Zimmer P, Trebing S, Timmers-Trebing U, et al. Eight-week, multimodal exercise counteracts a progress of chemotherapy-induced peripheral neuropathy and improves balance and strength in metastasized colorectal cancer patients: a randomized controlled trial. Support Care Cancer 2018;26:615–24. doi: 10.1007/s00520-017-3875-5

24 Dhawan S, Andrews R, Kumar L, et al. A randomized controlled trial to assess the effectiveness of muscle strengthening and balancing exercises on chemotherapy-induced peripheral neuropathic pain and quality of life among cancer patients. Cancer Nurs 2020;43:269–80. doi: 10.1097/ncc.0000000000000693

25 Kleckner IR, Park SB, Streckmann F, et al. Systematic review of exercise for prevention and management of chemotherapy-induced peripheral neuropathy. In: Lustberg M, Loprinzi C, eds. Diagnosis, Management and Emerging Strategies for Chemotherapy-Induced Neuropathy: A MASCC Book. Cham: Springer International Publishing 2021:183–241.

26 Higgins J, Savović J, Page M, et al. Assessing risk of bias in a randomized trial. In: Higgins J, Thomas J, Chandler J et al., eds. Cochrane Handbook for Systematic Reviews of Interventions. 2nd ed. Chichester (UK): John Wiley & Sons 2019:736.

27 McGuinness LA, Higgins JPT. Risk-of-bias visualization (robvis): an R package and shiny web app for visualizing risk-of-bias assessments. Res Synth Methods 2021;12:55–61. doi: 10.1002/jrsm.1411

28 Béliveau A, Boyne DJ, Slater J, et al. BUGSnet: an R package to facilitate the conduct and reporting of Bayesian network meta-analyses. BMC Med Res Methodol 2019;19:196. doi: 10.1186/s12874-019-0829-2

29 Müller J, Weiler M, Schneeweiss A, et al. Preventive effect of sensorimotor exercise and resistance training on chemotherapy-induced peripheral neuropathy: a randomised-controlled trial. Br J Cancer 2021;125:955–65. doi: 10.1038/s41416-021-01471-1

30 Şimşek NY, Demir A. Cold application and exercise on development of peripheral neuropathy during taxane chemotherapy in breast cancer patients: a randomized controlled trial. Asia Pac J Oncol Nurs 2021;8:255–66. doi: 10.4103/apjon.apjon-2075

31 Saraboon C, Siriphorn A. Effects of foam pad balance exercises on cancer patients undergoing chemotherapy: a randomized control trial. J Bodyw Mov Ther 2021;28:164–71. doi: 10.1016/j.jbmt.2021.07.013

32 Kleckner IR, Kamen C, Gewandter JS, et al. Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial. Support Care Cancer 2018;26:1019–28. doi: 10.1007/s00520-017-4013-0

33 Streckmann F, Kneis S, Leifert JA, et al. Exercise program improves therapy-related side-effects and quality of life in lymphoma patients undergoing therapy. Ann Oncol 2014;25:493–9. doi: 10.1093/annonc/mdt568

34 Schwenk M, Grewal GS, Holloway D, et al. Interactive sensor-based balance training in older cancer patients with chemotherapy-induced peripheral neuropathy: a randomized controlled trial. Gerontology 2016;62:553–63. doi: 10.1159/000442253

35 Vollmers PL, Mundhenke C, Maass N, et al. Evaluation of the effects of sensorimotor exercise on physical and psychological parameters in breast cancer patients undergoing neurotoxic chemotherapy. J Cancer Res Clin Oncol 2018;144:1785–92. doi: 10.1007/s00432-018-2686-5

36 Stuecher K, Bolling C, Vogt L, et al. Exercise improves functional capacity and lean

body mass in patients with gastrointestinal cancer during chemotherapy: a single-blind RCT. Support Care Cancer 2019;27:2159–69. doi: 10.1007/s00520-018-4478-5

37 Clark PG, Cortese-Jimenez G, Cohen E. Effects of reiki, yoga, or meditation on the physical and psychological symptoms of chemotherapy-induced peripheral neuropathy: a randomized pilot study. J Evid-Based Complement Altern Med 2012;17:161–71. doi: 10.1177/2156587212450175

38 Streckmann F, Lehmann HC, Balke M, et al. Sensorimotor training and whole-body vibration training have the potential to reduce motor and sensory symptoms of chemotherapy-induced peripheral neuropathy-a randomized controlled pilot trial. Support Care Cancer 2019;27:2471–78. doi: 10.1007/s00520-018-4531-4

39 Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365–76. doi: 10.1093/jnci/85.5.365

40 Cella D, Peterman A, Hudgens S, et al. Measuring the side effects of taxane therapy in oncology: the functional assesment of cancer therapy-taxane (FACT-taxane). Cancer 2003;98:822–31. doi: 10.1002/cncr.11578

41 Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993;11:570–9. doi: 10.1200/jco.1993.11.3.570

42 Calhoun EA, Welshman EE, Chang CH, et al. Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer 2003;13:741–8. doi: 10.1111/j.1525-1438.2003.13603.x

43 Tanay MAL, Armes J, Moss-Morris R, et al. A systematic review of behavioural and exercise interventions for the prevention and management of chemotherapy-induced peripheral neuropathy symptoms. J Cancer Surviv 2023;17:254–77. doi: 10.1007/s11764-021-00997-w

44 Courneya KS, McKenzie DC, Mackey JR, et al. Effects of exercise dose and type during breast cancer chemotherapy: multicenter randomized trial. J Natl Cancer Inst 2013;105:1821–32. doi: 10.1093/jnci/djt297

45 Dannecker EA, Koltyn KF. Pain during and within hours after exercise in healthy adults. Sports Med 2014;44:921–42. doi: 10.1007/s40279-014-0172-z

46 Chou YJ, Lai YH, Lin BR, et al. Factors influencing amount of weekly exercise time in colorectal cancer survivors. Cancer Nurs 2017;40:201–08. doi: 10.1097/ncc.0000000000000383

47 Lindell M, Grimby-Ekman A. Stress, non-restorative sleep, and physical inactivity as risk factors for chronic pain in young adults: a cohort study. PLoS One 2022;17:e0262601. doi: 10.1371/journal.pone.0262601

Figure and Table Legends

Figure 1. PRISMA flow diagram

Figure 2. Forest plots of the effects of exercise on patient-reported outcomes. (A) Quality of life (QOL), (B) Patient-reported CIPN symptoms, (C) Pain

Figure 3. Network meta-analysis(A) network graph, (B) SUCRA plot, (C) League Table Heatmap. The values in each cell show the relative treatment effect and 95% credible intervals of the treatment on the top, compared to the treatment on the left. The double asterisks: statistical significance.

Table 1. Overview of included studies

Table 2. Summary of main results regarding the effect of exercise on outcomes

Supplementary materials

Table S1. The detail of search strategy in this study

Table S2. Enrollment, completion rate and adherence

Figure S1. Funnel plot of comparison: Exercise versus control, outcome. (A) Quality of life (QOL), (B) Patient-reported CIPN symptoms, (C) Pain

Figure S2. Risk of bias assessment

Table 1. Overview of included studies

Author and Year	Exercise Type	Patients	Details of Exercise	Main Outcome Measures †
Streckmann et al.	Aerobic	Lymphoma, mixed chemo types	~1 hr/d, 2 d/wk, 36 wk	Baseline, after 12, 24, and 36 wk
2014 [33]	Balance	Unclear baseline CIPN presence	In the clinic, supervised	**EORTC QLQ-C30**
	Strength	N = 61 (total) N = 30 (exercise)	Aerobic: warm-up on a bicycle dynamometer (60–70% HR max), 10–30 min on a treadmill or bicycle dynamometer (70–80% HR max) at the end of the session	Vibration
		2 arms	Balance: four postural stabilization exercises, progressively increasing exercise difficulty as well as surface instability (20 s exercise +20 s rest for 3 sets, 1 min rest between different exercises)	Balance control (on static/dynamic surface)
			Strength: four different resistance exercises performed with Thera-Bands, at maximum resistance.	Incremental step test
Schwenk et al.	Balance	Mixed cancers, chemo types	45 min/d, 2 d/wk, 4 wk	Baseline and post- intervention
2016 [34]		Established CIPN	In the clinic, unsupervised	FES-1 (fear of falling)
		N = 22 (total) N = 11 (exercise)		**Balance** (feet close/semi tandem, eyes open/feet close, eyes closed)
		2 arms		Gait-speed variability
Vollmers et al.	Balance	Breast cancer, during paclitaxel treatment	2d/wk, during chemotherapy and for 6 wk after chemotherapy	Baseline, at the last dose of chemotherapy and at the 6-wk follow-up
2018 [35]	Strength	Unclear baseline CIPN presence	Balance: no dose specified	EORTC QLQ CIPN 20 EORTC QLQ-C30 EORTC-BR23
		N = 43 (total) N = 21 (exercise)	Strength: 6 exercises, 2 sets of 20 reps, RPE: 13-15 (moderate intensity)	**Posturometry sway area** **Fullerton Advanced Balance Scale scores**
		2 arms		Hand dynamometer Chair rising test

Zimmer et al.	Aerobic	Gastrointestinal cancers, oxaliplatin treatment	60 min/d, 2d/w, 8wk	Baseline, postintervention(8 wk), and12 wk
2018 [23]	Balance	Established CIPN	In a sports center, supervised	**FACT/GOG-TOI** FACT/GOG-NTX
	Strength	N = 30 (total) N = 17 (exercise)	Aerobic: cross-trainer, ergometer or walking; 10 min, 60-70% HRmax	GGT-Reha
		2 arms	Balance: 10 min	Strength: e1RM 6MWT
			Strength: 5 exercises; 20 min; 60-80% of e1RM; Borg CR10 scale level: 6	
Kleckner et al.	Aerobic	Mixed cancers, chemo types	Daily, 6wk	Baseline and post- intervention
2018 [32]	Strength	Most patients reported mild baseline CIPN	Home based, unsupervised	**Numbness (NRS)** **Tingling (NRS)** **Hot/coldness in hands/feet (NRS)**
		N = 456 (total) N = 231 (exercise)	Aerobic: walking; 60-85% of heart rate reserve	
		2 arms	Strength: resistance exercise; 3-5 RPE	
Stuecher et al.	Aerobic	Gastrointestinal cancers, mixed chemo types	12 wk	Before chemotherapy, after 2 cycles, after 12 weeks
2019 [36]		Unclear baseline CIPN presence	Home based, unsupervised	Vibration
		N = 44 (total) N = 22 (exercise)	150 min, moderate walking per week	Postural sway
		2 arms	Borg's self-rating of RPE of 11-13	**SPPB** Gait speed Lower-extremity muscle strength
Clark et al.	Yoga*	Mixed cancers, platinum treatment	60 min/w, 6wk	Baseline and post-intervention
2012 [37]		Established CIPN	In the clinic, supervised	FACT-GOG-Ntx Brief Symptom Inventory – 18
		N = 36 (total) N = 9 (exercise)	Low intensity	
		4 arms		
Streckmann et al.	Balance	Mixed cancers, chemo types	2d/wk, 6wk	Baseline and post-intervention

2019 [38]		Established CIPN	In the clinic, supervised	FACT GOG-Ntx EORTC-QLQ-C30 Pain-DETECT
		N = 40 (total) N = 20 (exercise)	Balance: on progressively unstable surfaces; 4 exercises; 3 sets of 20 s	**Achilles tendon reflex** **Deep sensitivity** **Patellar tendon reflex** **Light-touch perception** **Sense of position** Nerve conduction velocity and amplitude
		4 arms	Whole-body vibration: stand on a vibration platform; 4 sets of 30-s to 1-min	Balance control
		Balance/Whole-body vibration/Control/Healthy control		**Lower-leg strength** Gait speed Postural sway
Dhawan et al.	Balance	Mixed cancers, carboplatin + paclitaxel	30 min/d, daily, 10 wk	Baseline and post-intervention
2020 [24]	Strength	Established CIPN	Home based, unsupervised	CIPNAT **LANSS** **EORTC-QLQ**
		N = 45 (total) N = 22 (exercise)		
		2 arms		
Müller et al.	Balance	Mixed cancers, chemo types	During chemotherapy	Baseline, post- intervention and 3 and 6 wk after the intervention
2021 [29]	Strength	No baseline CIPN	Balance: 35 min/d, 3/wk, at home (unsupervised) or in the hospital (supervised)	**TNS** EORTC QLQ-CIPN 15 EORTC QLQ-C30 FES-1 (fear of falling)
		N = 170 (total) N = 112 (exercise)	Strength: 45 min/d, 2/wk, machine-based & 15 min/d, 1/wk, home-based	Nerve conduction studies
		3 arms		Postural control (Balance)
		Balance/Strength/Control		Lower-extremity score
				Chemotherapy completion rate
Şimşek and Demir	Balance	Breast cancer, mixed chemo types	15-30 min/d, 5d/wk, 12 wk	Baseline and post-intervention

2021 [30]	Strength	Established CIPN	Home based, supervised	**<u>CIPN Assessment Tool</u>**
		N = 90 (total) N = 30 (exercise)	Balance: 4 exercises	
		3 arms	Strength: 7 exercises	
		Exercise/cold application/control	10 reps/set for the first 3 wk, then 20 reps/set for 3 wk, and then 30 reps/set for 3 wk	
Saraboon and Siriphorn	Balance	Ovary or cervix cancer, paclitaxel regimens	During chemotherapy	Baseline, during intervention (4 wk) and postintervention (6 wk)
2021 [31]		No baseline CIPN	60 min/d, 2d/wk, 6 wk	FAB
		N = 30 (total) N = 15 (exercise)		MDNS
		2 arms		FACT-Taxane
				SPPB

†, Primary endpoint is written in bold and underlined. *, Relaxation-based hatha yoga consisting of weekly lessons and daily self-practice.

CIPN: chemotherapy-induced peripheral neuropathy, CIPNAT: Chemotherapy-Induced Peripheral Neuropathy Assessment Tool, DASH: Disability of the Arm, Shoulder, and Hand, e1RM: estimated one-repetition maximum, EORTC QLQ: the European Organization for Research and Treatment of Cancer core quality of life questionnaire, FAB: Fullerton Advanced Balance, FACT-GOG: Functional Assessment of Cancer Therapy/Gynecologic Oncology Group, TOI: Trial Outcome Index, Ntx: Neurotoxicity, FACT-Taxane: Functional Assessment of Cancer Therapy-Taxane, FES-1: falls efficacy scale-1, HR: heart rate, LANSS: Leeds Assessment of Neuropathic Symptoms and Sign, MDNS: Michigan Diabetic Neuropathy Score, NPRS: Numeric Pain Rating Scale, NRS: number rated scale, RPE, rate of perceived exertion, S-LANSS: Self-report version of Leeds Assessment for Neuropathic Symptoms and Signs, SPPB: short physical performance battery, TNS: total neuropathy score

Table 2. Summary of main results regarding the effect of exercise on outcomes

Study	Quality of Life (QOL)	Patient-reported CIPN	Pain	Clinical assessments of CIPN signs	Balance measures	Physical functional assessments
Intergroup comparison						
Streckmann et al. 2014 [33]	**Improvement in QOL within the first 12 weeks** Δ_{T1-T0} (Mean): IG 9.1, CG -6.15, P = 0.028		No significant difference	**Reduced peripheral deep sensitivity after 36 weeks** IG 87.5% (symptom diminished), CG 0%, P < 0.001	**Reduced sway paths after 36 weeks** Δ_{T3-T0}: static left P = 0.035, dynamic left P = 0.007, dynamic right P = 0.045 **Improvement in failed attempts** Δ_{T3-T0}: static left P = 0.024, dynamic left P = 0.014, dynamic right P < 0.001 **Improvement in time to regain balance after 36 weeks** Δ_{T3-T0} (Median): IG -0.26, CG 0.2, P = 0.045	No significant difference
Schwenk et al. 2016 [34]		No significant difference			**Reduced sway of hip, ankle, and center of mass (CoM) post intervention** Feet close – eyes open P = 0.010–0.022 (except anterior-posterior CoM sway) Semitandem – eyes open P = 0.008–0.035 (except ankle sway)	No significant difference
Vollmers et al. 2018 [35]	No significant difference				**Smaller sway area** Monopedal stance T1 (after the last dose) (left and right) both P < 0.001, T2 (6 weeks follow-up) (left) P = 0.003, T2 (right) P<0.01 Bipedal stance P = 0.039 **Improvement in postural stability** Δ_{T1-T0}: IG +1.35, CG -2.84, P < 0.001	**Less loss of strength in hand dynamometry** IG 0.60, CG -1.60, P = 0.029
Zimmer et al. 2018 [23]	No significant difference	**Less aggravation of neuropathic symptoms** Mean (T0/T1[after the intervention]/T2[after 4 weeks follow-up]): IG 33.12/35.24/34, CG 34.08/28.97/29.43 Δ_{T1-T0}: P = 0.002, Δ_{T2-T0}: P = 0.015			**Improvement in advanced static balance** Mean (T0/T1/T2): IG 11.47/13.35/12.47, CG 11/9.92/9.62 Δ_{T1-T0}: P = 0.025, Δ_{T2-T0}: P = 0.025	**Increased muscle strength** Bench press Δ_{T1-T0}: P = 0.014, Δ_{T2-T0}: P = 0.014 Leg press Δ_{T1-T0}: P = 0.001, Δ_{T2-T0}: P = 0.011 Lat pulldown Δ_{T1-T0}: P = 0.022, Δ_{T2-T0}: P = 0.031

Kleckner et al. 2018 [32]		**Less severe CIPN symptoms at postintervention** Hot/coldness in hands/feet Coefficient: -0.46, P = 0.045				
Stuecher et al. 2018 [36]					**Improvement in postural sway after 12 weeks** Δ_{T2-T0} (Mean): IG -58.8, CG 58.7, P = 0.003 (Group effect)	No significant difference
Streckmann et al. 2019 [38]	No significant difference	No significant difference	**Reduction of pain** F(2,25) = 3.575, P = 0.043	**Improvement in Achilles tendon reflex** F(2,26) = 4.791, P = 0.017 **Improvement in patellar tendon reflex** F(2,25) = 4.564, P = 0.020 **Improvement in peripheral deep sensitivity** F(2,25) = 5.548, P = 0.010		
Dhawan et al. 2020 [24]	**Better QOL after 10 weeks** Mean: IG 61.7, CG 43.1, P = 0.002	**Less severe, distressing, or frequent CIPN symptoms after 10 weeks** Mean: IG 83.1, CG 140.8, P < 0.0001	**Less neuropathic pain after 10 weeks** Mean: IG 10.7, CG 15.8, P = 0.001			
Müller et al. 2021 [29]	No significant difference	No significant difference	No significant difference	No significant difference	**Keeping average time of standing on one leg with open eyes at 3 weeks after chemotherapy** Adjusted between-group difference: Sensorimotor training vs. CG 2.2, P = 0.045 Resistance training vs. CG 2.3, P = 0.023	**Maintained muscle strength** Adjusted between-group difference: Resistance training vs. CG 11.1, P = 0.045
Şimşek and Demir 2021 [30]		**Less severe CIPN symptoms after 12 weeks** Numbness in the hand Mean: IG 1.9, Cold application 3.0, CG 3.1, P = 0.009 Numbness in the foot Mean: IG 3.8, Cold application 4.0, CG 5.5, P = 0.009	No significant difference			
Saraboon and Siriphorn 2021 [31]	No significant difference	No significant difference			**Invariant balance performance** Mean: IG 37.40, CG 34.13, P < 0.01	**Maintained baseline physical performance** Mean: IG 11.47, CG 10.67, P = 0.03
Intragroup comparison						
Clark et al. 2012 [37]	No significant difference	**There were no significant changes in IG whereas neuropathic symptoms**				

	worsened in CG. Mean, pre vs. post IG: 30.31 vs. 32.43, P = 0.278 CG: 31.14 vs. 27.86, P = 0.03

CIPN: chemotherapy-induced peripheral neuropathy, IG: intervention group, CG: control group

Figure 1


Identified records through database screening
(n=1640)
Records identified through previously published systematic reviews (n=9)
Excluded by title and abstract screening
(n=1609)
After 1st screening
(n=31)
Full text reviewed
(n=40)
Excluded by full-text review (n=28)
Review article: n=7
Wrong study design: n=14
Not evaluating effects of exercise on CIPN: n=5
Intervention was only for the upper extremity: n=2
Included for qualitative synthesis
(n=12)

Figure 2

A. QOL

Study or Subgroup	Exercise Mean	Exercise SD	Exercise Total	Control Mean	Control SD	Control Total	Weight	Std. Mean Difference IV, Random, 95% CI
Clark et al. [37]	116.8	11.46	7	110.17	20.25	7	8.6%	0.38 [-0.68, 1.44]
Dhawan et al. [24]	61.7	20.5	22	43.1	18.9	23	20.1%	0.93 [0.31, 1.55]
Müller et al. [29]	59.8311	20.7139	103	56.4	22.7	56	40.1%	0.16 [-0.17, 0.49]
Saraboon and Siriphorn [31]	155.27	7.39	15	148.87	8.98	15	15.3%	0.76 [0.01, 1.50]
Zimmer et al. [23]	82.637	15.432	17	77.897	12.032	13	15.9%	0.33 [-0.40, 1.06]
Total (95% CI)			**164**			**114**	**100.0%**	**0.45 [0.12, 0.78]**

Heterogeneity: Tau² = 0.04; Chi² = 5.78, df = 4 (P = 0.22); I² = 31%
Test for overall effect: Z = 2.65 (P = 0.008)



B. Patient-reported CIPN symptoms

Study or Subgroup	Exercise Mean	Exercise SD	Exercise Total	Control Mean	Control SD	Control Total	Weight	Std. Mean Difference IV, Random, 95% CI
Clark et al. [37]	32.43	3.55	7	27.86	9.82	7	8.0%	0.58 [-0.50, 1.66]
Dhawan et al. [24]	-83.1	46.5	22	-140.8	42.9	23	15.1%	1.27 [0.62, 1.91]
Kleckner et al. [32]	-1.1	1.9814	170	-1.64	2.344	185	27.0%	0.25 [0.04, 0.46]
Müller et al. [29]	-14.8524	16.3692	103	-14.3	15.3	56	23.9%	-0.03 [-0.36, 0.29]
Saraboon and Siriphorn [31]	-0.07	0.26	15	-0.33	0.62	15	13.2%	0.53 [-0.20, 1.26]
Zimmer et al. [23]	35.2353	6.6	17	28.974	9.92	13	12.8%	0.74 [-0.01, 1.49]
Total (95% CI)			**334**			**299**	**100.0%**	**0.46 [0.11, 0.82]**

Heterogeneity: Tau² = 0.11; Chi² = 14.90, df = 5 (P = 0.01); I² = 66%
Test for overall effect: Z = 2.54 (P = 0.01)



C. Pain

Study or Subgroup	Excercise Mean	Excercise SD	Excercise Total	Control Mean	Control SD	Control Total	Weight	Std. Mean Difference IV, Random, 95% CI
Dhawan et al. [24]	-10.7	5.6	22	-15.8	4.1	23	31.9%	1.02 [0.40, 1.65]
Müller et al. [29]	-22.8854	26.2218	103	-24.4	29.3	56	35.5%	0.06 [-0.27, 0.38]
Şimşek and Demir [30]	-3.4	2.2	30	-6.3	1.5	30	32.6%	1.52 [0.94, 2.10]
Total (95% CI)			**155**			**109**	**100.0%**	**0.84 [-0.11, 1.80]**

Heterogeneity: Tau² = 0.64; Chi² = 21.80, df = 2 (P < 0.0001); I² = 91%
Test for overall effect: Z = 1.73 (P = 0.08)



Figure 3





C

Comparator \ Treatment	Control	Aerobic+Balance+Strength	Balance	Balance+Strength	Strength	Yoga
Control		4.69 (-5.14, 14.56)	1.79 (-6.64, 10.22)	**18.62** (7.07, 30.19)	4.79 (-3.17, 12.72)	6.76 (-10.45, 23.99)
Aerobic+Balance+Strength	-4.69 (-14.56, 5.14)		-2.90 (-15.82, 10.01)	13.94 (-1.29, 29.02)	0.10 (-12.55, 12.67)	2.09 (-17.81, 21.84)
Balance	-1.79 (-10.22, 6.64)	2.90 (-10.01, 15.82)		**16.83** (2.56, 31.10)	3.00 (-4.95, 10.94)	4.95 (-14.17, 24.18)
Balance+Strength	**-18.62** (-30.19, -7.07)	-13.94 (-29.02, 1.29)	**-16.83** (-31.10, -2.56)		-13.82 (-27.83, 0.19)	-11.87 (-32.51, 8.78)
Strength	-4.79 (-12.72, 3.17)	-0.10 (-12.67, 12.55)	-3.00 (-10.94, 4.95)	13.82 (-0.19, 27.83)		1.96 (-16.92, 21.00)
Yoga	-6.76 (-23.99, 10.45)	-2.09 (-21.84, 17.81)	-4.95 (-24.18, 14.17)	11.87 (-8.78, 32.51)	-1.96 (-21.00, 16.92)	

Figure S1.

A. QOL



B. Patient-reported CIPN symptoms



C. Pain



Figure S2.


Risk of bias domains
D1
D2
D3
D4
D5
Study
Streckmann et al. [33]
Schwenk et al. [34]
Vollmers et al. [35]
Zimmer et al. [23]
Kleckner et al. [32]
Stuecher et al. [36]
Clark et al. [37]
Streckmann et al. [38]
Dhawan et al. [24]
Müller et al. [29]
Şimşek and Demir [30]
Saraboon and Siriphorn [31]
Domains:
D1: Bias arising from the randomization process.
D2: Bias due to deviations from intended intervention.
D3: Bias due to missing outcome data.
D4: Bias in measurement of the outcome.
D5: Bias in selection of the reported result.
Judgement
High
Some concerns
Low